摘要
目的:本研究旨在调查膳食益生元摄入量与阿尔茨海默病 (AD) 风险之间的关系。 方法:这项纵向研究包括 1,837 名老年人(≥65 岁)参与者,他们参加了一项基于多种族社区的队列研究,他们在基线时没有痴呆,并从食物频率问卷中提供了饮食信息。果聚糖(最著名的益生元之一)的每日总摄入量是根据食用频率和每份 8 种食物的果聚糖含量计算得出的。使用 Cox 比例风险模型检查每日果聚糖摄入量与 AD 风险的关联,并根据队列招募波、年龄、性别、种族/民族、教育、每日热量摄入和 APOE 基因型进行调整。通过在 Cox 模型中包含交互项以及分层分析,测试了种族/民族、APOE 基因型和性别的影响修正。 结果:在 1,837 名参与者(1,263 名女性 [69%];平均 [SD] 年龄 = 76 [6.3] 岁)中,平均随访 7.5 年(13736 人-年)期间发生了 391 例 AD 病例。每多摄入一克果聚糖,AD 风险降低 24%((95% CI)=0.60-0.97;P =0.03)。对吸烟、饮酒和合并症指数的额外调整并没有显着改变结果。尽管分层分析表明,果聚糖摄入与西班牙裔的 AD 风险降低显着相关,但与非西班牙裔黑人或白人无关。 结论:较高的膳食果聚糖摄入量与老年人临床阿尔茨海默病风险降低有关。
关键词: 膳食益生元消耗、阿尔茨海默病、痴呆症、APOE 基因型、中枢神经系统 (CNS)、帕金森病、多发性硬化症。
Current Alzheimer Research
Title:Association of Dietary Prebiotic Consumption with Reduced Risk of Alzheimer’s Disease in a Multiethnic Population
Volume: 18 Issue: 12
关键词: 膳食益生元消耗、阿尔茨海默病、痴呆症、APOE 基因型、中枢神经系统 (CNS)、帕金森病、多发性硬化症。
摘要:
Objective: This study aimed to investigate the association between dietary prebiotic intake and risk for Alzheimer’s disease (AD).
Methods: This longitudinal study includes 1,837 elderly (≥65 years) participants of a multi-ethnic community-based cohort study who were dementia-free at baseline and had provided dietary information from food frequency questionnaires. Total daily intake of fructan, one of the best-known prebiotics, was calculated based on consumption frequency and fructan content per serving of 8 food items. The associations of daily fructan intake with AD risk were examined using a Cox proportional hazards model, adjusted for cohort recruitment wave, age, gender, race/ethnicity, education, daily caloric intake, and APOE genotype. Effect modification by race/ethnicity, APOE genotype, and gender was tested by including an interaction term into the Cox models, as well as by stratified analyses.
Results: Among 1,837 participants (1,263 women [69%]; mean [SD] age = 76 [6.3] years), there were 391 incident AD cases during a mean follow-up of 7.5 years (13736 person-years). Each additional gram of fructan intake was associated with 24% lower risk for AD ((95% CI)=0.60-0.97; P =0.03). Additional adjusting for smoking, alcohol consumption, and comorbidity index did not change results materially. The associations were not modified by race/ethnicity, gender, and APOE genotype, although stratified analyses showed that fructan intake was significantly associated with reduced AD risk in Hispanics but not in non-Hispanic Blacks or Whites.
Conclusion: Higher dietary fructan intake is associated with a reduced risk of clinical Alzheimer’s disease among older adults.
Export Options
About this article
Cite this article as:
Association of Dietary Prebiotic Consumption with Reduced Risk of Alzheimer’s Disease in a Multiethnic Population, Current Alzheimer Research 2021; 18 (12) . https://dx.doi.org/10.2174/1567205019666211222115142
DOI https://dx.doi.org/10.2174/1567205019666211222115142 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Functional Imaging Combined with Multi-Detector CT: A Radionuclide Imaging Perspective
Current Medical Imaging Targeting Mitochondrial Dysfunction in Chronic Heart Failure: Current Evidence and Potential Approaches
Current Pharmaceutical Design Phase I Clinical Trial of Exherin (ADH-1) in Patients with Advanced Solid Tumors
Current Clinical Pharmacology Measurement of the Endogenous Adenosine Concentration in Humans In Vivo: Methodological Considerations
Current Drug Metabolism Rheumatoid Arthritis: An Autoimmune Disease with Female Preponderance and Cardiovascular Risk Equivalent to Diabetes Mellitus: Role of Cardiovascular Magnetic Resonance
Inflammation & Allergy - Drug Targets (Discontinued) A1 Adenosine Receptor Agonists: Medicinal Chemistry and Therapeutic Potential
Current Pharmaceutical Design Basic and Clinical Research Against Advanced Glycation End Products (AGEs): New Compounds to Tackle Cardiovascular Disease and Diabetic Complications
Recent Advances in Cardiovascular Drug Discovery (Discontinued) The Role of Phospholipase D Enzyme(s) in Modulating Cell Signaling: Implications for Cancer Drug Development
Current Bioactive Compounds Therapeutic Use of Nitric Oxide Scavengers in Shock and Sepsis
Current Pharmaceutical Design Investigational Positive Inotropic Agents for Acute Heart Failure
Cardiovascular & Hematological Disorders-Drug Targets Endothelial Progenitor Cells and Vascular Biology in Diabetes Mellitus: Current Knowledge and Future Perspectives
Current Diabetes Reviews Neuroprotective Gene Therapy for Parkinson’s Disease
Current Gene Therapy Gene Therapy for Familial Hypercholesterolemia
Current Pharmaceutical Design Detrimental Effects of Hyperglycemia in Acute Coronary Syndromes: from Pathophysiological Mechanisms to Therapeutic Strategies
Mini-Reviews in Medicinal Chemistry Brain Excitatory/Inhibitory Circuits Cross-Talking with Chromogranin A During Hypertensive and Hibernating States
Current Medicinal Chemistry Chinese Herbal Medicine for Hyperlipidaemia: A Review Based on Data Mining from 1990 to 2016
Current Vascular Pharmacology Mesenchymal Stromal Cells (MSCs): A Promising Tool for Cell-Based Angiogenic Therapy
Current Gene Therapy CPP-conjugated Anti-apoptotic Peptides as Therapeutic Tools of Ischemiareperfusion Injuries
Current Pharmaceutical Design A Novel Treatment Strategy for Sepsis and Septic Shock Based on the Interactions between Prostanoids, Nitric Oxide, and 20-Hydroxyeicosatetraenoic Acid
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Coronary CT and the Coronary Calcium Score, the Future of ED Risk Stratification?
Current Cardiology Reviews